论文部分内容阅读
美国食品药品管理局于1986年12月5日公布了一项法则,要求在含有亚硫酸盐作为无活性成分的处方药物的标签上,需要附注警告性说明,并于1987年6月3日开始生效。在警告性说明中要注明药品含有什么亚硫酸盐成分,例如焦亚硫酸钠,可能会使某些敏感的病人发生变态型反应,产生过敏症状以及可能威胁病人的生命,或造成哮喘发作。据报道有些病人,特别是哮喘病人,在应用含亚硫酸盐成分的药品后,发生严重
On December 5, 1986, the U.S. Food and Drug Administration published a rule requiring that a warning note be required on the label of prescription drugs containing sulphite as an inactive ingredient, beginning on June 3, 1987 Effective. In the cautionary note, indicate which sulfite ingredients in the drug, such as sodium metabisulfite, may cause allergic reactions in some sensitive patients, produce allergic symptoms and may threaten the patient’s life, or cause an asthma attack. It has been reported that some patients, especially those with asthma, developed serious problems with sulfite-containing medicines